|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:business_model
|
biopharmaceutical development
|
|
gptkbp:ceo
|
gptkb:Kevin_O'_Connor
|
|
gptkbp:clinical_trial
|
ongoing
Phase 1
Phase 2
Phase 3
|
|
gptkbp:collaboration
|
academic institutions
|
|
gptkbp:collaborations
|
gptkb:Johns_Hopkins_University
gptkb:Stanford_University
gptkb:University_of_California,_San_Francisco
gptkb:University_of_Pennsylvania
gptkb:MIT
|
|
gptkbp:collaborator
|
gptkb:Harvard_University
|
|
gptkbp:focus
|
gptkb:gene_therapy
|
|
gptkbp:founded
|
gptkb:2018
|
|
gptkbp:founder
|
gptkb:Kevin_O'_Connor
|
|
gptkbp:funding
|
over $100 million
|
|
gptkbp:goal
|
curative therapies.
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tessera Therapeutics
|
|
gptkbp:instruction_set
|
diverse
|
|
gptkbp:invention
|
multiple granted
|
|
gptkbp:investment
|
gptkb:Sofinnova_Partners
gptkb:Bessemer_Venture_Partners
gptkb:Canaan_Partners
gptkb:Series_B
gptkb:Flagship_Pioneering
GV (formerly Google Ventures)
Maverick Ventures
|
|
gptkbp:is_a_platform_for
|
Gene Writing technology
|
|
gptkbp:leadership
|
experienced team
|
|
gptkbp:mission
|
transform lives through gene therapy.
|
|
gptkbp:number_of_employees
|
50-100
|
|
gptkbp:partnership
|
gptkb:Novartis
|
|
gptkbp:partnerships
|
biotech companies
|
|
gptkbp:product
|
Tessera Gene Writing Platform
|
|
gptkbp:publications
|
numerous
|
|
gptkbp:region
|
global
|
|
gptkbp:regulatory_compliance
|
FDA approved
|
|
gptkbp:research_and_development
|
active
|
|
gptkbp:research_areas
|
oncology
|
|
gptkbp:research_focus
|
genetic disorders
rare diseases
neurological disorders
cardiovascular diseases
infectious diseases
metabolic diseases
disease modification
|
|
gptkbp:technology
|
DNA synthesis
Gene Writing
|
|
gptkbp:type_of_therapy
|
genetic medicine
|
|
gptkbp:website
|
www.tesseratherapeutics.com
|
|
gptkbp:bfsParent
|
gptkb:Ginkgo_Bioworks
|
|
gptkbp:bfsLayer
|
4
|